ATXA Therapeutics

23/12/2025

From all of us at ATXA Therapeutics, we wish you and yours a joyful and restful holiday season, and every success and happiness in 2026!

18/11/2025

ATXA Founder & CEO Therese Kinsella is joining leading global, public and private companies from the biotechnology & pharmaceutical sectors at Jefferies Global Healthcare Conference 2025 in London. Stay tuned for updates about the event with

31/03/2025

ATXA Therapeutics CEO & Founder Therese Kinsella was recently featured in the Business Post discussing the company's current fundraising and the plans to bring NTP42 through clinical trials in patients. Read more here...

ATXA, which is currently in the process of raising the €30 million, has been supported by Enterprise Ireland

28/02/2025

💜🌍 Today is Rare Disease Day! 🌍💜

Together, we stand with the 300 million people worldwide living with rare diseases. In uniting on this day we can raise awareness, advocate for change, and promote a more equitable future! ⚖️

Let’s use this moment to recognise and highlight the voices and stories of the rare disease community.

Share your story. Share your advocacy. Share your voice.

Go to our website to learn more: https://www.rarediseaseday.org/

24/02/2025

Rare is not rare. Taken together, over 300 million people worldwide are affected by a rare disease. on Friday, February 28 calls for equity in access to diagnosis, treatment & care for all people with a rare disease.
Rare Disease Day EURORDIS-Rare Diseases Europe

20/12/2024

On behalf of all of us here at ATXA Therapeutics, we wish you and yours a very happy and peaceful holiday season and the very best for 2025!

12/04/2024

Professor Therese Kinsella, Founder and CEO of ATXA Therapeutics, was the recipient of the main 2024 NovaUCD Innovation Award during an event held in the UCD University Club on April 11, 2024. These annual awards recognise excellence in innovation and of the successes achieved in the commercialisation of University College Dublin research over a number of years.

On receiving the award, Professor Kinsella said, “It is indeed a great honour for me to accept this Award from UCD both personally and on behalf of everyone on the ATXA team who have been part of our success journey so far.”

Read more at: https://www.ucd.ie/innovation/news-and-events/latest-news/2024-novaucd-innovation-awards/name,744339,en.html

29/02/2024

Have you got your social media pledge cards ready? 📝🌍

Available to download from our website, our pledge cards are written in 8 languages, allowing you to show your passion for Rare Disease Day, in your local contexts!

Download them today alongside our other resources by clicking on our website here: https://www.rarediseaseday.org/downloads/. Show your support for the international rare disease community today! 💻💡

26/02/2024

Why is it important to raise awareness?🤔

Bringing awareness to rare diseases is crucial as it sheds light on the specific challenges faced by those affected. From struggling to get a correct diagnosis due to limited knowledge among healthcare professionals to the financial burden of accessing expensive treatments, people often face uphill battles.

Moreover, the absence of tailored support networks can lead to feelings of isolation and misunderstanding. By sharing their stories and advocating for greater understanding, we can pave the way for improved resources, research, and ultimately, better quality of life. 💙

20/02/2024

Countdown alert! Just 10 days left until Rare Disease Day! 🎉

Let's come together to raise awareness and support for those living with rare conditions. Got something special planned? Don't forget to submit your events! Illuminate the world in solidarity with 💡, advocate for better resources and understanding, and share our stories to inspire change. Together, we're stronger! 💪

22/12/2023

On behalf of all at ATXA, we wish you all a happy and peaceful holiday season and the very best for the New Year!

21/12/2023

In first-in-human Phase 1 trials, ATXA Therapeutics' NTP42:KVA4 is safe and well tolerated, with favorable PK/PD characteristics and evidence of specific TP target engagement. These findings, combined with compelling preclinical efficacy data, support the continued development of NTP42 for the treatment of cardiopulmonary diseases, including PAH.

Check out our paper, published today in Frontiers in Pharmacology...

Background: The thromboxane receptor (TP) antagonist NTP42 is in clinical development for treatment of cardiopulmonary diseases, such as pulmonary arterial hypertension. In this randomized, placebo-controlled Phase I clinical trial, NTP42, administered as the oral formulation NTP42:KVA4, was evaluat...